Company Nymox Pharmaceutical Corporation Nasdaq
Equities
CA67076P1027
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Director/Board Member | - | 23-03-20 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 20-02-05 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 06-06-07 |
Paul Averback
CEO | Chief Executive Officer | 73 | 95-05-29 |
Director/Board Member | 88 | 15-06-30 | |
Director/Board Member | - | 23-03-20 | |
Patrick Doody
BRD | Director/Board Member | - | 23-07-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 93,265,000 | 54,049,529 ( 57.95 %) | 0 | 57.95 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+3.30% | 43.84B | |
+8.48% | 41.68B | |
+45.55% | 41.25B | |
-10.92% | 27.04B | |
+9.48% | 25.53B | |
-25.56% | 18.18B | |
+0.38% | 12.29B | |
+28.69% | 12.29B | |
+6.89% | 11.15B |
- Stock Market
- Equities
- NYMXF Stock
- Stock
- Company Nymox Pharmaceutical Corporation